It's estimated that over 70 million people around the world have chronic Hepatitis C infection and nearly 400,000 people die each year from Hepatitis C-related liver diseases. "Chronic Hepatitis C is a significant public health burden in India. When we launched Mylan's Hepato Care division in January 2015, we did so to increase access to critical, life-saving medicines for patients with chronic HCV and other liver-related conditions," said Mylan President Rajiv Malik.
"The launch of the fixed-dose combination of MyHep All is part of this mission and will help patients adhere to their chronic HCV treatment regimen," he added. The MyHep All launch follows Mylan's successful January 2016 launch of MyHep LVIR (Ledipasvir/Sofosbuvir combination) in India.
Mylan has the non-exclusive right to manufacture and distribute Velpatasvir/Sofosbuvir in approximately 100 developing countries via a license agreement from Gilead Sciences.